About Us
SunRegen Healthcare AG
is a biopharmaceutical company with a mission to develop drugs to treat neurodegenerative diseases

We focus on innovative treatments for patients suffering from neurological, neuromuscular and ophthalmic diseases. Our first product candidates in development target primary optical atrophy. We are further evaluating them for use in serious neurological / neuromuscular diseases such as ALS, Huntington's, Alzheimer’s and Parkinson’s disease.

Our team is composed of passionate and innovative founders and experts who have solid track records in drug development and clinical research in multinational pharmaceutical companies or management experience in international technology enterprises. Their determination in bringing life-changing treatments to patients encompasses everything they do.

Drug Development
Our solutions
SunRegen is developing drug candidates with the following characteristics:
  • Strong neuroprotective effects against multiple misfolded protein aggregate
  • Strong neurite outgrowth promoting effects.
  • Neuroregenerative effects indicated at in vivo level.
  • Anticipated favourable safety and tolerability profile.
  • With a good uptake by the brain.
  • News
    SunRegen Healthcare AG is leveraging the global pharmaceutical development ecosystem and building partnerships with professional CROs/CMOs, academic institutions, and service organizations related to pharmaceutical development.
    We have received funding from local investors, e.g. Go-Beyond, and international investors.
    Should you be interested to invest in SunRegen Healthcare AG please forward your inquiry to: investor@sunregen.ch
    Join us
    We welcome experienced scientists from the CNS field or industry experts from preclinical/clinical development to contact us. Pls send your CV and motivation letter to hr@sunregen.ch
    Contact Us

      SunRegen Healthcare AG


      Switzerland Innovation Park Basel Area

      Gewerbestrasse 24, 4123 Allschwil


    • PHONE

    • EMAIL